VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology VI.2.2 Summary of treatment benefits
|
|
- Philip Stephens
- 5 years ago
- Views:
Transcription
1 VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pulmonary arterial hypertension (a high blood pressure in the blood vessels in the lungs) is a rare disease. Historically, the incidence rates for pulmonary arterial hypertension (PAH) were estimated to be 1-2 cases per million adults, the National Institute of Health Registry in During the last three years, there has been an increase in the amount of epidemiological data on PAH and its underlying conditions. The latest incidence and occurrence rates for PAH in adults are estimated to be and cases per million, respectively, according to registry-based French and Scottish data. Furthermore, it is now recognised that PAH may manifest in both genders and all ages. The occurrence of PAH is more frequent in females (approximately 2:1 ratio). 2, 3 VI.2.2 Summary of treatment benefits This is a generic medicine (a medicine that is developed to be the same as a reference medicine that has already been authorized). Thus, extensive medical literature is available for sildenafil in the proposed therapeutic indications. VI.2.3 Unknowns relating to treatment benefits The safety of sildenafil has not been studied in patients with any known rare inherited eye disease such as retinitis pigmentosa. There are no data from the use of sildenafil in pregnant women. The effect of the long term use of sildenafil on the risk of death is unknown. Also, the safety of sildenafil in patients with impaired kidney function and underlying heart and blood vessel disease is not fully known.
2 VI.2.4 Summary of safety concerns Important identified risks: Risk What is known Preventability Drug interactions with organic nitrate, bosentan (and other CYP3A4 inducers) Concomitant use of nitrates and sildenafil can cause profound and prolonged drops in blood pressure. For this reason, it is not recommended to use sildenafil in patients who take medicines containing nitrates or nitric oxide such as amyl nitrate (medicines usually given for relief of angina pectoris or chest pain). Sildenafil and bosentan are often co-administered for pulmonary arterial hypertension (high blood pressure in the lungs) treatment. The blood level of sildenafil can be decreased by half if co-administered with bosentan, though the clinical significance of this remains uncertain. The effective use of sildenafil in Yes. Before starting sildenafil treatment, the patient should inform their treating doctor or pharmacist if they are taking, have recently taken, or might take medicines containing nitrates, bosentan or carbamazepine, phenytoin, phenobarbital, St John s Wort (herbal medicinal product) and rifampicin. The effective use of sildenafil should be closely monitored in patients using concomitant potent CYP3A4 inducers, such as St. John s Wort (herbal medicinal product), rifampicin, carbamazepine, phenytoin and phenobarbital, and if required the sildenafil dose should be adjusted.
3 Sickle cell crisis (vasoocclusive crisis) in patients with sickle cell disease Increased risk of death in children and adolescents (increased relative mortality in the paediatric population) patients already on bosentan therapy has not been demonstrated. Cytochrome P450 3A4 (CYP3A4), is an important enzyme in the body, mainly found in the liver and in the intestine. It helps with the breaking down of medicines, so that they can be removed from the body. Sildenafil is mainly broken down by CYP450 enzyme. Therefore, sildenafil clearance may be increased when used simultaneously with potent CYP3A4 inducers, such as St. John s Wort (herbal medicinal product), rifampicin (used to treat bacterial infections), carbamazepine, phenytoin, and phenobarbital (used, among others, to treat epilepsy). A vaso-occlusive crisis is a common painful complication due to an abnormality of red blood cells. Events of vaso-occlusive crises requiring hospitalization were reported more commonly in patients taking sildenafil. For children and adolescent patients aged 1 year to 17 years old, the recommended sildenafil dose in patients less than equal to 20 kg is 10 mg three times a day and for patients more than 20 kg is Yes. Sildenafil should not be used in patients with pulmonary hypertension secondary to sickle cell anaemia (a decrease in the amount of red blood cells or 51haemoglobin in the blood). Before taking sildenafil, the patient should inform their treating doctor if they are having an abnormality of red blood cells. Yes. Sildenafil should not be used at doses higher than the recommended doses in paediatric patients with pulmonary arterial
4 Nose bleeds (epistaxis)/bleeding events 20 mg (1 tablet) three times a day. Higher than recommended doses should not be used in children and adolescents patients with pulmonary arterial hypertension (high blood pressure in the lungs). The 20 mg tablet should not be used in cases where 10 mg three times a day should be administered in younger patients. Other pharmaceutical forms are available for administration to patients less than or equal to 20 kg and other younger patients who are not able to swallow tablets. In the long term pediatric study, an increase in deaths was observed in patients who were administered higher than the recommended dose of sildenafil. There is no information on the safety of the administration of sildenafil in patients with bleeding disorders or active peptic ulceration (stomach ulcer). There may be a potential for increased risk of bleeding when sildenafil is initiated in patients with high blood pressure in the blood vessels in the lungs who are already using a Vitamin K antagonist (medicines that reduce blood clotting by reducing the action of vitamin K). Nose bleed is the most common (may affect up to 1 in 10 people) side effect reported with sildenafil use. hypertension (high blood pressure in the blood vessels in the lungs). Yes. Before taking sildenafil, the patient should inform their treating doctor if they currently have a stomach ulcer, a bleeding disorder (such as haemophilia), or problems with nose bleeds. Sildenafil should only be administered to these patients after a careful benefit-risk assessment. Important potential risks: Risk What is known
5 Decreased blood pressure (hypotension) An eye problem, usually due to loss of blood flow to the optic nerve (non-arteritic anterior ischaemic optic neuropathy) Hearing loss Hypotension has been reported at an unknown frequency (frequency cannot be estimated from the available data) with sildenafil use. Sildenafil should not be used in patients with very low blood pressure (< 90/50 mmhg). When prescribing sildenafil, physicians should carefully consider patients with hypotension as they could be adversely affected by sildenafil s mild to moderate vasodilatory effects (widening of blood vessels). Caution is advised when sildenafil is administered to patients taking an alpha-blocker therapy (e.g. doxazosin) for the treatment of high blood pressure or prostate problems, as the combination of the two medicines may cause symptoms resulting in the lowering of blood pressure (e.g. dizziness, light headedness). NAION refers to a loss of blood flow to the optic nerve (a nerve that connects the eye to the brain). NAION is a side effect reported with sildenafil use at an unknown frequency. Patients should not take sildenafil if they have ever had loss of vision because of NAION. Patients are advised to contact a doctor immediately if they experience any sudden decrease or loss of vision while taking sildenafil. A sudden decrease or loss of hearing has been reported with sildenafil use at an unknown frequency. An acute bleeding into the lungs due to unapproved use of sildenafil in paediatric population (pulmonary haemorrhage in off-label paediatric patients) Drug interactions with epoprostenol, iloprost, guanylate cyclase stimulators, and PDE5 inhibitors As safe and effective use of sildenafil is not known in children below 1 year of age, sildenafil should not be given to children below 1 year of age. Co-administration of oral sildenafil and intravenous epoprostenol in patients with pulmonary arterial hypertension (high blood vessels in the lungs) resulted in the occurrence of new adverse events of blurred vision, nasal congestion, night sweats, back pain, dry mouth, and hyperaemia (an excess of blood in the vessels supplying an organ or other part of the body), along with known adverse reactions of headache, flushing, pain in extremity and oedema (abnormal fluid accumulation in tissues or body cavities). The safe and effective use of sildenafil co-administered with other treatments for pulmonary arterial hypertension (eg, iloprost) has not been studied. Therefore, care is advised in cases of co-administration. The co-administration of PDE5 inhibitors, including sildenafil, with guanylate cyclase stimulators such as riociguat (used for treatment of high blood pressure in the lungs), is contraindicated as it may potentially lead to symptomatic hypotension. Patients should inform their treating doctor or pharmacist if they are taking, have recently taken, or might take epoprostenol, iloprost, riociguat or other PDE5 inhibitors.
6 Missing information: Risk What is known Long-term eye (ocular) safety The safety of sildenafil has not been studied in patients with known rare inherited eye diseases such as retinitis pigmentosa, and therefore its use is not recommended. Safety in pregnancy Safety in patients with impaired kidney function (renal impairment) Safety in patients with heart and blood vessel disease (cardiovascular diseases) Long-term death (mortality) There are no data regarding the use of sildenafil in pregnant women. If a patient is pregnant, thinks they may be pregnant, or are planning to have a baby, the patient should ask their doctor or pharmacist for advice before taking this medicine. Sildenafil should not be used during pregnancy unless strictly necessary. Patients should inform their treating doctor if they are having kidney problems as the sildenafil dose may need to be adjusted. Initial dose adjustments are not required in patients with severe kidney problems. A downward dose adjustment to 20 mg twice daily should be considered after a careful benefitrisk assessment, but only if therapy is not well-tolerated. Sildenafil should not be used in patients who have recently had a stroke or a heart attack. Serious cardiovascular events have been reported with the use of sildenafil. Most, but not all, of these patients had pre-existing cardiovascular risk factors. The efficacy of the long term use of sildenafil in adult patients with high blood pressure in the blood vessels in the lungs was studied. A long term survival status was studied for a minimum of 3 years. However, the effect of sildenafil on the risk of death in adult patients with PAH is unknown. VI.2.5 Summary of additional risk minimization measures by safety concern Summary of Product Characteristics (SPC) of Sildenafil Amneal 20 mg film-coated tablets provides physicians, pharmacists and other health care professionals with details on how to use the medicine, the risks and recommendations for minimising them. An abbreviated version of this in lay language is provided in the form of the package leaflet (PIL). All these risk minimization measures are given in the SPC and PIL of Sildenafil Amneal 20 mg film- coated tablets. This medicine has no additional risk minimization measures. VI.2.6 Planned Post-Authorisation Development Plan No post-authorisation study is planned for this product.
7 VI.2.7 Summary of changes to the Risk Management Plan over time Version Date Safety Concerns Comment Important Identified Risks: o Hypersensitivity to sildenafil or to any of the excipients o Co-administration with nitric oxide donors (such as amyl nitrite) or nitrates in any form o Combination with the most potent of the CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) o Patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION) o Use in severe hepatic impairment o Use in recent history of stroke or myocardial infarction o Use in severe hypotension (blood pressure < 90/50 mmhg) at initiation o Use in retinitis pigmentosa o Patients with hypotension, fluid depletion, severe left ventricular outflow obstruction, or autonomic dysfunction o Cardiovascular risk factors o Patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie s disease), or in patients who have conditions which may predispose them to priapism o Patients with pulmonary hypertension Initial submission
8 secondary to sickle cell anaemia o Visual events Important Potential Risks: o Co-administration with alpha-blocker o Bleeding disorders o Vitamin K antagonists o Veno-occlusive disease o Use of sildenafil with bosentan o Concomitant use with other PDE5 inhibitors Missing Information: o Use during pregnancy o Use during breastfeeding o Use in children below 1 year Important Identified Risks: o Drug interactions with nitrate, bosentan (and other CYP3A4 inducers) o Vasoocclusive crisis in patients with sickle cell disease o Increased relative mortality in the paediatric population o Epistaxis/bleeding events Important Potential Risks: o Hypotension o Non-arteritic anterior ischaemic optic neuropathy (NAION) o Hearing loss o Pulmonary haemorrhage in off-label paediatric patients o Drug interactions with epoprostenol, iloprost, guanylate cyclase stimulators, and PDE5 inhibitors Missing Information: o Long-term ocular safety o Safety in pregnancy Safety concerns have been updated as per Agency s suggestion. o Safety in patients with renal impairment o Safety in patients with cardiovascular diseases o Long-term mortality
9 Important Identified Risks: o Drug interactions with organic nitrate, bosentan (and other CYP3A4 inducers) o Vasoocclusive crisis in patients with sickle cell disease o Increased relative mortality in the paediatric population o Epistaxis/bleeding events Important Potential Risks: o Hypotension o Non-arteritic anterior ischaemic optic neuropathy (NAION) o Hearing loss o Pulmonary haemorrhage in off-label paediatric patients o Drug interactions with epoprostenol, iloprost, guanylate cyclase stimulators, and PDE5 inhibitors Missing Information: o Long-term ocular safety o Safety in pregnancy o Safety in patients with renal impairment o Safety in patients with cardiovascular diseases o Long-term mortality Safety concerns have been updated as per Agency s suggestion.
10 Summary EU-Risk Management Plan NL/H/3654/001/DC - Sildenafil Amneal
ASSURANS Tablets (Sildenafil citrate)
Published on: 21 Jan 2016 ASSURANS Tablets (Sildenafil citrate) Composition Each film-coated tablet contains: Sildenafil Citrate IP equivalent to Sildenafil... 20 mg Colour: Titanium Dioxide IP Dosage
More informationPackage leaflet: information for the user. Sildenafil 25 mg, 50 mg and 100 mg film-coated tablets Sildenafil
Package leaflet: information for the user Sildenafil 25 mg, 50 mg and 100 mg film-coated tablets Sildenafil Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPackage leaflet: Information for the user. Tadalafil Sigillata 20 mg film-coated tablets. tadalafil
Package leaflet: Information for the user Tadalafil Sigillata 20 mg film-coated tablets tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPackage leaflet: Information for the user. Tadalafil Sigillata 5 mg film-coated tablets. tadalafil
Package leaflet: Information for the user Tadalafil Sigillata 5 mg film-coated tablets tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the patient. Sildenafil 25 mg, 50 mg and 100 mg film-coated tablets Sildenafil
Package leaflet: Information for the patient Sildenafil 25 mg, 50 mg and 100 mg film-coated tablets Sildenafil Read all of this leaflet carefully before you start taking this medicine because it contains
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Sildenafil Pharmathen 25 mg film-coated tablets Sildenafil Pharmathen 50 mg film-coated tablets Sildenafil Pharmathen 100 mg film-coated tablets Sildenafil
More informationPackage leaflet: Information for the patient. Tadalafil Mylan 5 mg film-coated tablets Tadalafil
PACKAGE LEAFLET 1 Package leaflet: Information for the patient Tadalafil Mylan 5 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains
More informationIndications Rebound pulmonary hypertension caused by withdrawal of Nitric Oxide in paediatric patients on PICU (unlicensed indication).
Medicines Management & Pharmacy Services (MMPS) Guidelines on the use of sildenafil (Revatio) in acute pulmonary hypertension for paediatric cardiac patients Indications Rebound pulmonary hypertension
More informationPackage leaflet: Information for the patient. Vardenafil Krka 20 mg film-coated tablets. Vardenafil
PACKAGE LEAFLET Package leaflet: Information for the patient Vardenafil Krka 5 mg film-coated tablets Vardenafil Krka 10 mg film-coated tablets Vardenafil Krka 20 mg film-coated tablets Vardenafil Read
More informationVIAGRA connect Pharmacy Introduction
VIAGRA connect Pharmacy Introduction February 2018, PP-PHE-GBR-0046 COECT Agenda Agenda References Understanding Erectile Dysfunction (ED) Introducing VIAGRA connect Supplying VIAGRA connect Summary Essential
More informationPackage leaflet: Information for the user. CIALIS 2.5 mg film-coated tablets Tadalafil
Package leaflet: Information for the user CIALIS 2.5 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. Tadalafil 5 mg film-coated tablets. tadalafil
Package leaflet: Information for the user Tadalafil 5 mg film-coated tablets tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. CIALIS 10 mg film-coated tablets Tadalafil
Package leaflet: Information for the user CIALIS 10 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationSee available DOSAGES and PACKAGES. View prices
See available DOSAGES and PACKAGES View prices Levitra Generic SUMMARY OF PRODUCT CHARACTERISTICS NAME OF THE MEDICINAL PRODUCT Levitra Generic film-coated tablets User Information Levitra Generic orodispersible
More informationPackage leaflet: Information for the patient. Tadalafil Krka 5 mg film-coated tablets Tadalafil
Package leaflet: Information for the patient Tadalafil Krka 5 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. CIALIS 2.5 mg film-coated tablets Tadalafil
Package leaflet: Information for the user CIALIS 2.5 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPackage leaflet: Information for the user. CIALIS 5 mg film-coated tablets Tadalafil
Package leaflet: Information for the user CIALIS 5 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information for
More informationSummary of the risk management plan (RMP) for Adempas (riociguat)
EMA/76215/2014 Summary of the risk management plan (RMP) for Adempas (riociguat) This is a summary of the risk management plan (RMP) for Adempas, which details the measures to be taken in order to ensure
More informationEplerenon Medical Valley + Eplerenon Stada
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Heart failure is a complex syndrome, clinically characterized by signs and symptoms secondary to abnormal cardiac function. It
More informationPackage leaflet: Information for the user. Tadalafil Actavis 20 mg film-coated tablets. tadalafil
PACKAGE LEAFLET 1 Package leaflet: Information for the user 20 mg film-coated tablets tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT VIAGRA 25 mg film-coated tablets VIAGRA 50 mg film-coated tablets VIAGRA 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology High blood pressure in lung vessels which carry blood away from the heart Several studies showed that spontaneous high blood pressure
More informationPackage leaflet: Information for the user Sildenafil Aurobindo 50 mg film-coated tablets Sildenafil Aurobindo 100 mg film-coated tablets Sildenafil
Package leaflet: Information for the user Sildenafil Aurobindo 50 mg film-coated tablets Sildenafil Aurobindo 100 mg film-coated tablets Sildenafil Read all of this leaflet carefully before you start taking
More informationPackage Leaflet: Information for the user. Vardenafil 5 mg tablets Vardenafil 10 mg tablets Vardenafil 20 mg tablets. vardenafil
Package Leaflet: Information for the user Vardenafil 5 mg tablets Vardenafil 10 mg tablets Vardenafil 20 mg tablets vardenafil Read all of this leaflet carefully before you start using this medicine because
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Revatio 20 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 20 mg of sildenafil
More informationCIALIS (See-AL-iss) (tadalafil) tablets
1 Patient Information CIALIS (See-AL-iss) (tadalafil) tablets Read this important information before you start taking CIALIS and each time you get a refill. There may be new information. You may also find
More informationVI.2 Elements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Product therapeutic indications: Myocardial infarction is the medical term for an event commonly known as a heart attack. It happens
More informationPART VI: SUMMARY OF THE RISK MANAGEMENT PLAN
PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN VI.1 Summary of activities in the risk management plan The summary below was prepared based on the information included in Part II, IV and V of the present
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT VIAGRA 25 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg of sildenafil (as citrate)
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) CANDESARTAN/HYDROCHLOROTHIAZIDE ORION 8 MG/12.5 MG, 16 MG/12.5 MG, 32 MG/12.5 MG, 32 MG/25 MG ORION CORPORATION DATE: 17-04-2015, VERSION 2 VI.2 Elements for
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Sildenafil ratiopharm 25 mg film-coated tablets Sildenafil ratiopharm 50 mg film-coated tablets Sildenafil ratiopharm 100 mg
More informationSandoz Ltd. Page 1 of 7 PL 04416/ SildeHEXAL SF 25 mg, 50 mg & 75 mg orodispersible film PACKAGE LEAFLET: INFORMATION FOR THE USER
Sandoz Ltd. Page 1 of 7 PACKAGE LEAFLET: INFORMATION FOR THE USER SildeHEXAL SF 25 mg orodispersible film SildeHEXAL SF 50 mg orodispersible film SildeHEXAL SF 75 mg orodispersible film Sildenafil Read
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Spedra 50 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg of avanafil. For the full list
More informationPATIENT INFORMATION LEAFLET AMLOC RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: AMLOC 5 mg tablets AMLOC 10 mg tablet Read all of this leaflet carefully before you start taking AMLOC. Keep this leaflet. You may need to read it
More informationPackage Leaflet: Information for the user
Package Leaflet: Information for the user Adempas 0.5 mg film-coated tablets Adempas 1 mg film-coated tablets Adempas 1.5 mg film-coated tablets Adempas 2 mg film-coated tablets Adempas 2.5 mg film-coated
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT CIALIS 2.5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg tadalafil. Excipient
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION Pr ADEMPAS Riociguat Tablets This leaflet is Part 3 of a three-part "Product Monograph" published when ADEMPAS was approved for sale in Canada and is designed specifically
More information6.2 Elements for a Public Summary
6.2 Elements for a Public Summary 6.2.1 Overview of disease epidemiology Invicorp is to be used for erectile dysfunction, also known as impotence, the inability to get and maintain an erection that is
More informationPackage Leaflet: Information for the user. Levitra 5 mg film-coated tablets Vardenafil
Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Vivanza 5 mg film-coated tablets. Vivanza 10 mg film-coated tablets Vivanza 20 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tadalafil Mylan 2.5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg tadalafil.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tadalafil Mylan 2.5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg tadalafil.
More informationPATIENT INFORMATION LEAFLET DYNAFIL RANGE
Scheduling Status: S4 Proprietary name, Strength and Pharmaceutical Form: DYNAFIL 25 mg (coated tablets) DYNAFIL 50 mg (coated tablets) DYNAFIL 100 mg (coated tablets) Please read this leaflet carefully
More informationPRODUCT MONOGRAPH. Sildenafil Tablets. 20 mg sildenafil (as sildenafil citrate) cgmp-specific Phosphodiesterase Type 5 Inhibitor
PRODUCT MONOGRAPH Pr APO-SILDENAFIL R Sildenafil Tablets 20 mg sildenafil (as sildenafil citrate) cgmp-specific Phosphodiesterase Type 5 Inhibitor Treatment of Pulmonary Arterial Hypertension APOTEX INC.
More informationPRODUCT MONOGRAPH REVATIO * sildenafil tablets 20 mg sildenafil (as sildenafil citrate)
PRODUCT MONOGRAPH Pr REVATIO * sildenafil tablets 20 mg sildenafil (as sildenafil citrate) sildenafil solution for injection 0.8 mg/ml sildenafil (as sildenafil citrate) cgmp-specific Phosphodiesterase
More information5. How to store VIAGRA CONNECT. 6. Contents of the pack and other information. 4. Possible side effects. Other side effects that have been reported
Other side effects that have been reported Warnings and precautions VIAGRA CONNECT with food and drink Very common (may affect more than 1 in 10 people): headache. Common (may affect up to 1 in 10 people):
More informationBefore you take CIALIS. When you must not take it
CIALIS tadalafil Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about CIALIS. It does not contain all the available information. It does not take the place
More informationThis leaflet answers some common questions about Silagra.
Silagra sildenafil citrate Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Silagra. It does not contain all the available information. It does not
More informationAll medicines have risks and benefits. Your doctor has weighed the risks of you taking CIALIS against the benefits they expect it will have for you.
CIALIS tadalafil Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about CIALIS. It does not contain all the available information. It does not take the place
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT CIALIS 2.5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg tadalafil. Excipient
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT VIAGRA 25 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg sildenafil as citrate.
More informationPackage Leaflet: Information for the user. Tadalafil 10 mg film-coated tablets Tadalafil
Package Leaflet: Information for the user Tadalafil 10 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Levitra 5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg of vardenafil (as hydrochloride).
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Coronary artery disease and as anticoagulant (inhibiting the clotting of the blood) in patients undergoing surgery to treat blockages
More informationPackage leaflet: Information for the patient
Package leaflet: Information for the patient Tadalafil Rowex 2.5 mg Film-coated tablets Tadalafil Rowex 5 mg Film-coated tablets Tadalafil Rowex 10 mg Film-coated tablets Tadalafil Rowex 20 mg Film-coated
More informationAUSTRALIAN PRODUCT INFORMATION REVATIO (sildenafil citrate)
AUSTRALIAN PRODUCT INFORMATION REVATIO (sildenafil citrate) 1. NAME OF THE MEDICINE Sildenafil (as citrate) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION REVATIO tablets contain 20 mg sildenafil (as the
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Sildenafil Actavis 25 mg film-coated tablets Sildenafil Actavis 50 mg film-coated tablets Sildenafil Actavis 100 mg film-coated
More informationPackage Leaflet: Information for the user. Tadalafil 20 mg film-coated tablets Tadalafil
Package Leaflet: Information for the user Tadalafil 20 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationPiazza G, Creager M. Thromboangiitis Obliterans. Circulation Apr 27; 121(16):
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Thromboangiitis Obliterans (TAO) 12 TAO, also called Buerger disease, is an inflammatory disease that most commonly affects the
More informationPackage leaflet: Information for the patient. Revatio 10 mg/ml powder for oral suspension Sildenafil
Package leaflet: Information for the patient Revatio 10 mg/ml powder for oral suspension Sildenafil Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationSildenafil Teva 25 mg film-coated tablets Each tablet contains sildenafil citrate equivalent to 25 mg of sildenafil.
1. NAME OF THE MEDICINAL PRODUCT Sildenafil Teva 25 mg film-coated tablets Sildenafil Teva 50 mg film-coated tablets Sildenafil Teva 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy or benign prostatic obstruction, is a condition in
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Tadalafil Mylan 2.5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg tadalafil.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT CIALIS 2.5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg tadalafil. Excipients:
More informationRISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: , VERSION 1.
RISK MANAGEMENT PLAN (RMP) PUBLIC SUMMARY ETORICOXIB ORION (ETORICOXIB) 30 MG, 60 MG, 90 MG & 120 MG FILM-COATED TABLET DATE: 07-10-2016, VERSION 1.2 VI.2 Elements for a Public Summary Etoricoxib Orion
More informationSandoz Ltd Sildenafil 25 mg Tablets PL 04416/1297
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Sildenafil 25 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Sildenafil 25 mg tablets Each tablet contains 25 mg of sildenafil
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER Nicorandil 10 mg Tablets Nicorandil 20 mg Tablets nicorandil
PACKAGE LEAFLET: INFORMATION FOR THE USER Nicorandil 10 mg Tablets Nicorandil 20 mg Tablets nicorandil Read all of this leaflet carefully before you start taking this medicine because it contains important
More informationPackage leaflet: Information for the user. Tadalafil Clonmel 5 mg film-coated tablets. Tadalafil
Package leaflet: Information for the user Tadalafil Clonmel 5 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationAPO-SILDENAFIL PHT 20 MG TABLETS
APO-SILDENAFIL PHT 20 MG TABLETS Product Information Australia NAME OF THE MEDICINE Sildenafil citrate Chemical Name: Sildenafil citrate is 1 -[4-ethoxy-3 -(6,7-dihydro-1-methyl-7-oxo-3-propyl-1Hpyrazolo[4,3-d]pyrimidin-5-yl)phenylsulphonyl]-4-methylpiperazine
More informationEach tablet contains sildenafil citrate equivalent to 25, 50 or 100 mg of sildenafil.
1. NAME OF THE MEDICINAL PRODUCT Sildenafil Actavis 25 mg film-coated tablets Sildenafil Actavis 50 mg film-coated tablets Sildenafil Actavis 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE
More informationSummary of safety concerns Important identified risks
Valley VI.2 Elements for a public summary NL/H/3661/001-002/DC - Ivabradin Medical VI.2.1 Overview of disease epidemiology Ivabradine is a medicine used for two long-term (chronic) heart conditions: to
More informationSILDENAFIL tablets, for oral use Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SILDENAFIL TABLETS safely and effectively. See full prescribing information for SILDENAFIL TABLETS.
More informationEtoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets , Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN
Etoricoxib STADA 30 mg, 60 mg, 90 mg and 120 mg film-coated tablets 23.5.2016, Version V1.2 PUBLIC SUMMARY OF THE RISK MANAGEMENT PLAN VI.2 Elements for a Public Summary Etoricoxib STADA 30 mg film-coated
More informationElements for a public summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Glaucoma is an eye disease that can result in damage to the optic nerve and loss of vision (blindness). It is the major cause
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationSummary of the risk management plan (RMP) for Ivabradine Anpharm (ivabradine)
EMA/518024/2015 Summary of the risk management plan (RMP) for Ivabradine Anpharm (ivabradine) This is a summary of the risk management plan (RMP) for Ivabradine Anpharm, which details the measures to be
More informationPATIENT INFORMATION LEAFLET CARZIN XL
SCHEDULING STATUS: S3 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: 4 mg film coated tablets. Read all of this leaflet carefully before you start taking. Keep this leaflet. You may need to read it
More informationSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Viagra Connect 50 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains sildenafil citrate equivalent
More informationScottish Medicines Consortium
Scottish Medicines Consortium sildenafil, 20mg (as citrate) tablets (Revatio ) No. (596/10) Pfizer Ltd 15 January 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationTADAFLO 5 Tablets (Tadalafil)
Published on: 16 Sep 2016 TADAFLO 5 Tablets (Tadalafil) Composition TADAFLO 5 Tablets Each tablet contains: Tadalafil.5 mg Dosage Form Tablet Pharmacology Pharmacodynamics Mechanism of Action Penile erection
More informationPULMOPRES Tablets (Tadalafil)
Published on: 20 Jan 2016 PULMOPRES Tablets (Tadalafil) Composition Each film-coated tablet contains: Tadalafil IP... 20 mg Colours Lake Indigo Carmine, Titanium Dioxide IP & Yellow Oxide of Iron Dosage
More informationAlphagra 100mg CH 3 O N CH 2 CO 2 H HOOC OH H S N O 2. GENERIC NAME Sildenafil Citratel
GEERIC AME CEMICAL AME oxo-3-propyl-1-pyrazolo[4,3-d]pyrimidin MLECULAR FRMULA C223064 C687 MLECULAR WEIGT PRPRIETARY AME: Alphagra DAGE FRM: 100mg ildenafil tablet for oral administration CMPITI Alphagra
More information20 mg film-coated tablets: Each film-coated tablet contains 20 mg vardenafil (as vardenafil hydrochloride trihydrate).
1. NAME OF THE MEDICINAL PRODUCT Vardegin 5 mg film-coated tablets Vardegin 10 mg film-coated tablets Vardegin 20 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 5 mg film-coated tablets:
More informationPackage leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets
Package leaflet: Information for the patient Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets Acetylsalicylic acid Read all of this leaflet carefully before you
More informationPackage leaflet: Information for the patient. Felodipin AstraZeneca 10 mg prolonged-release tablets. felodipine
Package leaflet: Information for the patient Felodipin AstraZeneca 2.5 mg prolonged-release tablets Felodipin AstraZeneca 5 mg prolonged-release tablets Felodipin AstraZeneca 10 mg prolonged-release tablets
More informationSummary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin)
EMA/247834/2014 Summary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin) Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised
More informationSUMMARY OF THE PRODUCT CHARACTERISTICS
SUMMARY OF THE PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Lekap 25 mg film-coated tablets Lekap 50 mg film-coated tablets Lekap 100 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Sildenafil Dr. Reddy s 100 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 140.48 mg
More information1. Name of the medicinal product Levitra 10 mg orodispersible tablets
1. Name of the medicinal product Levitra 10 mg orodispersible tablets 2. Qualitative and quantitative composition Each orodispersible tablet contains 10 mg of vardenafil (as hydrochloride). Excipients:
More informationSummary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Sildenafil 100 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 100 mg sildenafil (as
More informationSummary of the risk management plan (RMP) for Duloxetine Zentiva (duloxetine)
EMA/450483/2015 Summary of the risk management plan (RMP) for Duloxetine Zentiva (duloxetine) This is a summary of the risk management plan (RMP) for Duloxetine Zentiva, which details the measures to be
More informationPatient leaflet: Information for the user. Paracetamol Galpharm 500mg tablets paracetamol
Patient leaflet: Information for the user Paracetamol Galpharm 500mg tablets paracetamol [For medicines available only on prescription:] Read all of this leaflet carefully before you start taking this
More informationRisk Management Plan
Management Plan Active substance: VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Hypertension is generally defined as blood pressure higher than 140/90 mmhg. Hypertension may
More information